<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770899</url>
  </required_header>
  <id_info>
    <org_study_id>5441</org_study_id>
    <nct_id>NCT01770899</nct_id>
  </id_info>
  <brief_title>Evaluation Montelukast in the Treatment of Status Asthmaticus</brief_title>
  <official_title>A Prospective Analysis of the Use of Oral Montelukast in Children With Status Asthmaticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corrie Fletcher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advocate Center for Pediatric Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of oral montelukast (Singulair)&#xD;
      given with other standard asthma medications and treatments in the treatment of children with&#xD;
      status asthmaticus. Status asthmaticus is an acute asthma attack that does not respond to&#xD;
      standard intermittent treatments but requires a continuous medication to aid in breathing.&#xD;
      While new medications have been used to better manage chronic asthma, acute asthma&#xD;
      exacerbations continue to be a significant cause of hospitalization and even death in&#xD;
      children. Oral montelukast is a very safe medication that is used to manage chronic asthma in&#xD;
      children, but it has not been studied for use in status asthmaticus. If oral montelukast,&#xD;
      given with other standard therapies, can reduce the treatment length associated with severe,&#xD;
      acute asthma exacerbations in children, it could potentially improve both the morbidity and&#xD;
      burden of pediatric asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While new medications have been used to better manage chronic asthma, acute exacerbations&#xD;
      continue to be a significant cause of pediatric morbidity and mortality. Montelukast holds an&#xD;
      established role in the pediatric outpatient management of asthma and while two promising&#xD;
      studies in adults have demonstrated its potential use as an adjunctive therapy for acute&#xD;
      exacerbations, its similar use in pediatrics has yet to be established. This pilot study is&#xD;
      designed as a prospective, double blinded, randomized, controlled, clinical trial comparing&#xD;
      the use of oral montelukast plus standard of care vs. standard of care alone in children&#xD;
      admitted for status asthmaticus to the pediatric intensive care unit (PICU). The primary&#xD;
      outcome the investigators are interested in is the time to reach a Modified Pediatric Asthma&#xD;
      Score (PAS) of &lt; 5, which, per the clinical protocol for the treatment of status asthmaticus,&#xD;
      is the time when patients are able to come off continuous bronchodilator therapy. If oral&#xD;
      montelukast, given with other standard therapies, can reduce the treatment, emotional, and&#xD;
      financial burden (e.g., shortened intensive care stay) associated with severe, acute asthma&#xD;
      exacerbations in children, it would provide a significant therapeutic advantage, potentially&#xD;
      improving both the morbidity and burden of pediatric asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of pediatric asthma score</measure>
    <time_frame>Hourly during the length of the patient's pediatric ICU hospitalization for status asthmaticus</time_frame>
    <description>Measurement of pediatric asthma score hourly from admission assessing for time to improvement of score, an average length of stay predicted 2-4 days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo capsule given every 24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gelatin capsule given every 24 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Between ages 2-148 years&#xD;
&#xD;
          -  Requiring PICU admission for status asthmaticus&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  Pediatric asthma score &gt; 8 on admission&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Intubated patients or other patients unable to take medications by mouth secondary to&#xD;
             anatomic or pre-existing craniofacial issues&#xD;
&#xD;
          -  Patients already on montelukast as their controller medication&#xD;
&#xD;
          -  Patients with a known allergy to montelukast&#xD;
&#xD;
          -  Any patient with phenylketonuria (PKU)&#xD;
&#xD;
          -  Any patient currently on treatment with rifampin, fluconazole, or Phenobarbital&#xD;
             medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrie Fletcher, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advocate Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corrie E Fletcher, DO</last_name>
    <phone>708-684-1308</phone>
    <email>corrie.fletcher@advocatehealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Torero, MD</last_name>
    <phone>708-684-5685</phone>
    <email>luis.torero@advocatehealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advocate Children's Hospital Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrie Fletcher, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Advocate Center for Pediatric Research</investigator_affiliation>
    <investigator_full_name>Corrie Fletcher</investigator_full_name>
    <investigator_title>Pediatric Resident</investigator_title>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>Singulair</keyword>
  <keyword>status asthmaticus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

